Salivary Gland Cancer Clinical Trial
Official title:
The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial
Phase 2 clinical trial on the efficacy of cabozantinib in locally advanced, recurrent and/or metastatic salivary gland cancer patients.
Rationale: Salivary gland cancer (SGC) is a rare cancer with 24 histological subtypes. Treatment options for locally advanced and/or metastatic SGC are limited. The tyrosine kinase inhibitor cabozantinib suppresses tumor growth, angiogenesis, and metastasis, and has been approved for renal cell carcinoma and thyroid cancer. Cabozantinib may also be of value in advanced SGC because c-MET, one of the targets of cabozantinib, is frequently overexpressed in SGC. Objectives: To assess the objective response rate (ORR), progression free survival (PFS), overall survival (OS), duration of response (DoR), toxicity, and quality of life (QoL) of patients with advanced SGC treated with cabozantinib in 3 cohorts: salivary duct carcinoma (SDC), adenoid cystic carcinoma (ACC), other SGC's. Study design: Single arm, single center, phase II clinical trial in 3 cohorts: ACC, SDC and other SGC's. Study population: Patient with c-MET positive, locally advanced, recurrent, and/or metastatic SGC. Intervention: Cabozantinib tablets 60 mg once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01969578 -
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
|
Phase 2 | |
| Completed |
NCT01703455 -
Activity of Sorafenib in Salivary Gland Cancer
|
Phase 2 | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03781986 -
APG-115 in Salivary Gland Cancer Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT05483374 -
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
|
||
| Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03172624 -
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
|
Phase 2 | |
| Completed |
NCT00509002 -
Iressa Study in Patients With Salivary Gland Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05008237 -
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
|
Phase 2 | |
| Recruiting |
NCT03360890 -
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05898373 -
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
| Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
| Completed |
NCT01344356 -
Stereotactic Body Radiotherapy for Head and Neck Tumors
|
Phase 4 | |
| Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06091878 -
Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers
|